GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (FRA:YAG2) » Definitions » Shiller PE Ratio

Atossa Therapeutics (FRA:YAG2) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Atossa Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Atossa Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Atossa Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Shiller PE Ratio Chart

Atossa Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Atossa Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Atossa Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Atossa Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atossa Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Shiller PE Ratio falls into.



Atossa Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Atossa Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Atossa Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.046/131.7762*131.7762
=-0.046

Current CPI (Mar. 2024) = 131.7762.

Atossa Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -17.222 100.560 -22.568
201409 -18.158 100.428 -23.826
201412 -35.035 99.070 -46.601
201503 -21.622 99.621 -28.601
201506 -17.642 100.684 -23.090
201509 -25.019 100.392 -32.841
201512 -22.363 99.792 -29.530
201603 -10.560 100.470 -13.850
201606 -7.156 101.688 -9.273
201609 0.748 101.861 0.968
201612 -8.191 101.863 -10.596
201703 -60.588 102.862 -77.619
201706 -6.871 103.349 -8.761
201709 -1.770 104.136 -2.240
201712 -0.635 104.011 -0.805
201803 -6.877 105.290 -8.607
201806 -4.348 106.317 -5.389
201809 -0.548 106.507 -0.678
201812 0.185 105.998 0.230
201903 -0.549 107.251 -0.675
201906 -0.708 108.070 -0.863
201909 -0.327 108.329 -0.398
201912 -0.234 108.420 -0.284
202003 -0.290 108.902 -0.351
202006 -0.382 108.767 -0.463
202009 -0.289 109.815 -0.347
202012 -0.723 109.897 -0.867
202103 -0.034 111.754 -0.040
202106 -0.050 114.631 -0.057
202109 -0.034 115.734 -0.039
202112 -0.035 117.630 -0.039
202203 -0.036 121.301 -0.039
202206 -0.050 125.017 -0.053
202209 -0.061 125.227 -0.064
202212 -0.057 125.222 -0.060
202303 -0.047 127.348 -0.049
202306 -0.074 128.729 -0.076
202309 -0.047 129.860 -0.048
202312 -0.055 129.419 -0.056
202403 -0.046 131.776 -0.046

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Atossa Therapeutics  (FRA:YAG2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Atossa Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Atossa Therapeutics (FRA:YAG2) Business Description

Traded in Other Exchanges
Address
107 Spring Street, Seattle, WA, USA, 98104
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics (FRA:YAG2) Headlines

No Headlines